Search

A clinical trial, NCT06563479, is underway to investigate whether a personalized approach to chemoradiation therapy is as effective as standard therapy for individuals with HPV-positive throat cancer. The trial aims to determine if a lower dose of radiation combined with standard chemotherapy causes fewer side effects and how the different treatment approaches impact participants' quality of life. The trial is currently recruiting participants and is expected to be completed by August 31, 2027. It is being conducted at Memorial Sloan Kettering Cancer Center, with Dr. Nancy Lee as the principal investigator. [Extracted from the article]

A preprint abstract from biorxiv.org discusses a study on the potential of using extracellular vesicles (EVs) and iron oxide nanoparticles (IONP) to induce ferroptosis, a regulated cell death mechanism, in lung cancer cells. The researchers formulated a system called ExoFeR, which demonstrated efficient ferroptosis induction and was further enhanced by tumor-targeting transferrin (TF) conjugation. The study also found that ExoFeR and ExoFeRTF were able to sensitize chemo-resistant cancer cells, including cisplatin-resistant lung cancer patient-derived tumoroid organoids. This research presents a promising therapeutic approach for combating lung cancer by intrinsically inducing ferroptosis and sensitizing chemo-resistant cells. [Extracted from the article]

Astellas Pharma Inc. has been issued a patent for a combination therapy involving antibodies against Claudin 18.2 for the treatment of cancer. The therapy aims to effectively treat and prevent diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. The method involves administering an antibody that binds to CLDN18.2 in combination with an agent that stabilizes or increases the expression of CLDN18.2. The patent provides various embodiments and combinations of agents for the treatment of different types of cancer. [Extracted from the article]

A recent study from Addis Ababa University in Ethiopia discusses the occurrence of acute brachial artery occlusion following cisplatin-based chemotherapy. The research highlights that while the connection between cancer and venous thrombosis is well-known, the recognition of arterial thrombosis as a serious complication of cancer and chemotherapy is a recent development. The study presents a rare case of cisplatin-related brachial arterial thrombosis in a 50-year-old man with cholangiocarcinoma, emphasizing the importance of careful monitoring, suspicion, and prompt management to prevent serious complications and mortality. For more information, the full article can be accessed through SAGE Open Medical Case Reports. [Extracted from the article]

A recent study conducted by researchers at Hubei University of Medicine in Xiangyang, China, explored the use of ropivacaine as an adjunctive agent to enhance the effectiveness of cisplatin therapy in treating colorectal cancer (CRC). The study found that the co-administration of ropivacaine with cisplatin inhibited cell viability and migration, promoted apoptosis, and increased the sensitivity of CRC cells to cisplatin. This effect was achieved by promoting ferroptosis, a form of cell death, through the inhibition of SIRT1 expression. The findings suggest that ropivacaine could be a potential therapeutic approach for overcoming cisplatin resistance in CRC. [Extracted from the article]

A recent study conducted by researchers at Western Sydney University has revealed new findings on colon cancer. The study focused on the chemotherapeutic potential of chlorambucil-platinum(IV) prodrugs, which have shown promising anticancer activity. The prodrugs were found to induce changes in the microtubule cytoskeleton and DNA of colon cells, leading to apoptosis and necrosis. The study also identified dysregulated proteins and dysfunction in transcription, MAPK markers, microtubule-associated proteins, and mitochondrial transport. These findings suggest that chlorambucil-platinum(IV) prodrugs have the potential to be effective multi-mechanistic chemotherapeutics for colon cancer. [Extracted from the article]

A study conducted at Sun Yat-sen University in Guangzhou, China, investigated the effects of Ganoderma Lucidum Spore Oil (GLSO) on the tumor growth and survival of mice treated with cyclophosphamide (CTX). The study found that GLSO enhanced the anti-tumor effect of CTX and prolonged the survival of mice with H22 hepatocellular carcinoma. GLSO also showed no obvious toxicity to liver functions and decreased the level of urea in the mice. The study concluded that GLSO could potentially be used in combination with CTX to extend the survival of patients undergoing chemotherapy for hepatocellular carcinoma. [Extracted from the article]

A new study from Huazhong University of Science and Technology in Wuhan, China, explores the concept of pyroptosis in cancer treatment. Pyroptosis is a form of cell death that can be induced by the chemotherapy drug cisplatin. While cisplatin is effective in treating tumors, it can also cause inflammation and toxicity in healthy tissues. The study aims to identify molecular targets to optimize cisplatin treatment and minimize side effects. Future research may focus on targeted drug delivery systems and regulating gasdermin proteins to selectively modulate pyroptosis. This review provides valuable insights into potential therapeutic strategies for cancer treatment. [Extracted from the article]

A new study conducted by researchers at Providence Saint John's Health Center explores the impact of intra-tumoral immunity on predicting response and survival in patients with muscle-invasive bladder cancer (MIBC) who undergo neoadjuvant cisplatin-based chemotherapy (NAC) followed by cystectomy. The study found that patients who achieved a pathologic complete response (pCR) had lower neutrophil counts and neutrophil/lymphocyte ratios (NLR) in their peripheral blood, as well as an abundance of B cells and CD3+ T cells in the tumor microenvironment (TME). On the other hand, patients who did not achieve a pCR had increased protein expression of ARG1+ cells and immune checkpoint molecules in the TME. These findings suggest that considering the immune environment is important in determining the clinical outcome of MIBC patients treated with NAC. [Extracted from the article]

A recent study conducted by researchers at Alexandria University focused on the use of artemisinin, a compound derived from Artemisia annua, as a potential treatment for high-grade urothelial carcinoma. The study involved male albino mice that were divided into different groups and induced with urinary bladder cancer. The results showed that artemisinin treatment alone and artemisinin pre-treatment followed by cisplatin therapy led to down-regulation of FGFR3 and HRAS gene expression, up-regulation of P53 and KDM6A gene expression, and improvement in renal function and blood counts. Additionally, histological examination revealed a reduction in renal injury and a reversal of invasive urothelial carcinoma. The study suggests that artemisinin may have a significant effect in reversing the carcinogenesis process and enhancing the efficacy of cisplatin therapy. [Extracted from the article]

This document provides information about a clinical trial in China for the treatment of liver cancer. The trial aims to compare the effectiveness and safety of two different treatments, FOLFOX-HAIC and RALOX-HAIC, in patients with hepatocellular carcinoma. The trial plans to enroll 1115 patients with BCLC Stage B or C liver cancer who will receive either FOLFOX-HAIC or RALOX-HAIC treatment. The primary outcome measures include progression-free survival, time to progression, and adverse events, while secondary outcome measures include overall survival, objective response rate, and disease control rate. [Extracted from the article]

A recent study conducted at the University of Groningen in the Netherlands has found that patients with testicular cancer who undergo chemotherapy have an increased risk of developing early cardiovascular events. To identify patients at high risk, researchers used a vascular fingerprint tool that assessed five risk factors: smoking, overweight, hypertension, dyslipidemia, and diabetes mellitus. Patients with three or more risk factors were considered to have a high-risk vascular fingerprint and were found to have a higher risk of developing cardiovascular events. This tool can be used to develop preventative strategies, including anticoagulant treatment. [Extracted from the article]

A report from Mokpo National University in South Korea discusses research findings on colon cancer. The study focuses on the anticancer activity of a cyclic hexapeptide called deoxybouvardin (DB) in human colorectal cancer cells. The researchers found that DB suppressed the growth of both oxaliplatin-resistant and oxaliplatin-sensitive colorectal cancer cells by targeting specific signaling pathways, increasing reactive oxygen species levels, and disrupting mitochondrial function. The study suggests that DB has potential as a therapeutic agent for the treatment of oxaliplatin-resistant colorectal cancer. [Extracted from the article]

Researchers at Anhui Medical University in China have conducted a computational analysis of the solubility of the anti-cancer drug Temozolomide in supercritical carbon dioxide (SC-CO2). They used a dataset of pressure and temperature as input parameters and Temozolomide solubility as the output. Three regression models were employed to predict solubility, with the Support Vector Machine (SVM) regression model displaying the highest accuracy. The research suggests that SC-CO2 could be an efficient solvent for cancer therapy. [Extracted from the article]

A study conducted at Okayama University Hospital in Japan explored the efficacy of combining the chemokine receptor CXCR4 inhibitor AMD3100 with cisplatin, a platinum-based compound commonly used to treat oral squamous cell carcinoma (OSCC). The researchers found that the combination of AMD3100 and cisplatin had synergistic antitumor effects, leading to a significant reduction in tumor volume and extensive hemorrhage and necrosis. These findings suggest that the combination therapy could be a promising strategy for addressing cisplatin-resistant OSCC. The study was funded by the Japan Society for the Promotion of Science. [Extracted from the article]

A new study conducted by researchers at the National Autonomous University of Mexico (UNAM) explores the potential of S-allyl-cysteine (SAC) in treating glioblastomas, an aggressive form of cancer affecting the Central Nervous System. The study found that SAC, either alone or in combination with the chemotherapeutic drug temozolomide (TMZ), exhibited antitumor effects by regulating redox activity responses. SAC decreased cell viability in glioblastoma cell lines and enhanced the effects of TMZ. The researchers concluded that SAC has antioxidant properties and potential antitumor efficacy against glioblastomas. [Extracted from the article]

A recent study conducted by researchers at Wroclaw Medical University in Poland has found that the ethanol extract from the bark of the Madhuca longifolia tree, also known as Mahua, possesses potent cytotoxic activity against melanoma cells. The extract selectively targets cancer cells and induces apoptosis, while also increasing reactive oxygen species generation in melanoma cells. Furthermore, when used in combination with the chemotherapy drug dacarbazine, the extract enhances the anticancer activity of the drug. This research suggests that the ethanol extract of Madhuca longifolia could be a promising source of compounds for combination therapy in the treatment of melanoma. [Extracted from the article]

A recent study conducted by researchers at Hunan Normal University in China has identified a novel cancer-germline gene called DAZL that promotes the progression and cisplatin resistance of non-small cell lung cancer (NSCLC). The study found that DAZL is expressed exclusively in testis among normal human tissues but is ectopically expressed in NSCLC tissues. Overexpression of DAZL promoted tumor growth in a mouse xenograft model, while silencing DAZL suppressed cell proliferation, colony formation, migration, invasion, and cisplatin resistance. The study suggests that DAZL could be a potential therapeutic target for NSCLC. [Extracted from the article]

A study conducted by researchers at Renji Hospital in Shanghai, China, explores the use of a sponge-derived alkaloid called AP-7 as a sensitizer to cisplatin in the treatment of multidrug-resistant non-small cell lung cancer (NSCLC). The researchers found that AP-7 enhances the growth inhibition activity of cisplatin on multidrug-resistant NSCLC cells by disrupting cell cycle arrest and amplifying DNA damage effects. Additionally, the combination of AP-7 and cisplatin downregulates Chk1 activation, interrupts the DNA damage repair-dependent Chk1/CDK1 pathway, and promotes apoptosis in multidrug-resistant NSCLC cells. These findings suggest that AP-7 has the potential to be used as a sensitizer to cisplatin in the treatment of multidrug-resistant NSCLC. [Extracted from the article]

A study conducted at Anhui Medical University in Hefei, China, investigated the efficacy of a chemotherapy regimen consisting of oxaliplatin, fluorouracil, and calcium folinate in patients with advanced primary liver cancer. The study compared two groups of patients, one receiving conventional intravenous infusion and the other receiving hepatic arterial infusion chemotherapy. The research group showed higher overall effectiveness, better improvement of health status, and fewer complications compared to the control group. Additionally, the research group had lower levels of certain serum indices and higher one-year overall survival rates. The study concludes that hepatic arterial infusion chemotherapy with this regimen can improve clinical outcomes and increase survival rates in patients with advanced primary liver cancer. [Extracted from the article]

A new study conducted at the People's Hospital of Guangxi Zhuang Autonomous Region in Nanning, China, explores the role of SIVA-1 in gastric cancer (GC) chemotherapy. The study found that SIVA-1 expression is positively correlated with the sensitivity of GC to cisplatin (DDP), but not with other chemotherapy drugs. Additionally, the study revealed that SIVA-1 overexpression, in combination with DDP treatment, inhibits tumor growth in vivo. These findings suggest that SIVA-1 may serve as a predictive biomarker for cisplatin sensitivity in gastric cancer. [Extracted from the article]

A preprint abstract from medrxiv.org discusses the challenges in predicting the response to cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC). The lack of reliable biomarkers for treatment response makes it difficult to determine the benefit of NAC for many patients. The study conducted comprehensive transcriptomic and genomic profiling on tumors from 100 MIBC patients and identified genes associated with NAC response, as well as a novel signature related to the WNT signaling pathway. Machine learning models incorporating transcriptomic and genomic features showed promising performance in predicting NAC response. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A new report from researchers at Huazhong University of Science and Technology in Wuhan, China, discusses the development of resistance to chemotherapy in esophageal cancer and the search for effective therapeutic strategies. The study found that the expression of Mcl-1, a molecule involved in chemoresistance, increased in cells exposed to cisplatin, a commonly used drug in esophageal cancer therapy. The researchers discovered that capivasertib, a pan-Akt kinase drug, decreased Mcl-1 levels and enhanced the effects of cisplatin in chemo-resistant esophageal cancer cells. In mouse models, capivasertib significantly extended overall survival. The study highlights the potential of capivasertib to reverse chemo-resistance in esophageal cancer cells. [Extracted from the article]

A recent study conducted in Shanghai, China, has explored the potential of L-Theanine, a compound found in green tea, as an anti-cancer agent. The researchers investigated the effects of L-Theanine on lung cancer cells and found that it improved the resistance of these cells to cisplatin, a commonly used chemotherapy drug. The study also identified the STAT3/NOTCH1-BMAL1 signaling pathway as a potential mechanism through which L-Theanine exerts its effects. These findings suggest that L-Theanine may have therapeutic potential in overcoming chemoresistance in lung cancer and other types of cancer. [Extracted from the article]

A recent study conducted by researchers at Mustansiriyah University in Baghdad, Iraq, has found that the drug metformin can enhance the effectiveness of cisplatin chemotherapy in treating glioblastoma, a type of brain tumor. Metformin, commonly used to treat type 2 diabetes, was shown to synergistically inhibit the growth of glioblastoma cells and reduce DNA damage when used in combination with cisplatin. These findings suggest that metformin could be a valuable adjunct in enhancing the clinical effectiveness of chemotherapy regimens. Further research is needed to explore the potential utility of metformin in combination therapies for glioblastoma treatment. [Extracted from the article]

A recent study conducted at Children's Hospital in Cincinnati, Ohio, has found that inhibiting the activity of histone deacetylase (HDAC) can increase the effectiveness of cisplatin in eliminating metastatic cells in pediatric liver cancers. The researchers discovered that cancer-associated fibroblasts (CAFs) and neuron-like cells in the metastatic microenvironments of hepatoblastoma and hepatocellular carcinoma express high levels of HDAC1. By combining HDAC inhibition with cisplatin treatment, the researchers were able to eliminate CAFs and inhibit proliferation in these cancer cells. The study suggests that this combination therapy could be beneficial in treating pediatric liver cancers. [Extracted from the article]

A new survey conducted by the National Comprehensive Cancer Network (NCCN) reveals that cancer drug shortages continue to be a problem in the United States. While the shortage of the chemotherapy drugs carboplatin and cisplatin has improved, 89% of surveyed cancer centers still report shortages of various important anti-cancer agents and supportive care medications. These shortages not only burden patients, caregivers, and providers, but they can also delay clinical trials and hinder progress in developing new cancer therapies. The survey also found that drug shortages affect clinical trials and that sustainable, long-term solutions are needed to ensure a stable supply of high-quality cancer medications. The NCCN is advocating for economic incentives and increased transparency in the drug manufacturing industry to address these issues. [Extracted from the article]

A recent study conducted at the Cancer Institute Hospital in Tokyo, Japan, explored the use of a new drug called lecithinized human copper/zinc superoxide dismutase (Cu/Zn-SOD) in preventing oxaliplatin-induced peripheral neuropathy (PN). The study included 90 patients with colorectal cancer who were receiving postoperative adjuvant chemotherapy. The primary endpoint of the study, which was the occurrence of Grade 2 PN, did not occur. However, the study group did have a significantly greater number of cycles before Grade 2 PN and hypersensitivity reactions (HSR) occurred compared to the placebo group. The researchers concluded that the drug may suppress both PN and HSR, improving patient quality of life and prognosis. [Extracted from the article]

Researchers from the University of Agriculture Faisalabad in Pakistan have conducted a study on the effectiveness of boron oxide (B3O3) as a drug-delivery system for the anti-cancer drug melphalan. Using theoretical simulations, the researchers examined the structural, electrical, and energetic features of the drug-carrier complex. The study found that B3O3 shows potential as a promising vehicle for delivering melphalan, offering localized drug release near tumor cells and reducing secondary side effects. This research provides valuable insights into the interaction mechanism between melphalan and B3O3, highlighting the potential of B3O3 as a nanocarrier for cancer therapy. [Extracted from the article]

Researchers at the National Institute of Pharmaceutical Education and Research in Ahmedabad, India have developed a 3D-printed implant for the post-surgical adjuvant therapy of cisplatin-resistant cancer cells in oral cancer patients. The implant is made from biodegradable polymers blended with laser-responsive graphene and the chemotherapy drug cisplatin. When the implant is irradiated with a laser, the graphene generates hyperthermia events that lead to the destruction of cisplatin-resistant cancer cells. The implant also offers sustained drug release for 28 days and has shown promising results in reversing chemoresistance in tumor models. This research provides a potential approach for the adjuvant treatment of resistant oral cancer. [Extracted from the article]

A recent study conducted by investigators at AntiCancer Inc. in San Diego, California, has found that methionine restriction, combined with radiation and temozolomide (TMZ) chemotherapy, was highly effective in treating a teenage female patient with high-grade glioma. Gliomas are malignant primary brain tumors that are difficult to treat. The patient's tumor size shrunk by at least 60% after the start of methionine restriction, and her condition remained stable for 19 months without severe adverse effects. This research provides promising results for the treatment of gliomas using this combination therapy. [Extracted from the article]

A recent study conducted at the Huaiyin Institute of Technology in Huai'an, China, has developed six novel platinum(IV) complexes that show promise as targeted therapy options for hepatocellular carcinoma (HCC), a type of liver cancer. These complexes, which combine platinum(II) agents with glycyrrhetinic acid (GA), demonstrated superior antitumor activity against cancer cells, including cisplatin-resistant cells, and exhibited good liver-targeting ability. Complex 20, in particular, showed strong tumor inhibition ability with minimal systemic toxicity in xenograft models. The researchers concluded that complex 20 could potentially be developed as an effective anti-HCC agent for cancer treatment. [Extracted from the article]

Researchers at Virginia Tech's Fralin Biomedical Research Institute have made progress in finding a solution to chemotherapy resistance in glioblastoma, a deadly type of brain cancer. The current standard treatments for glioblastoma, including surgery, radiation, and chemotherapy using the drug temozolomide, have limited effectiveness and resistance to the drug develops rapidly. The researchers have identified a molecular signaling pathway called Phosphoinositide 3 Kinase (PI3K) that is crucial for cancer cell survival during temozolomide treatment. Blocking a specific form of the signaling protein called PI3K-beta made the tumor cells more sensitive to temozolomide treatment. However, delivering PI3K-beta inhibitors into the brain remains a challenge. [Extracted from the article]

A research report from Nantong University in Jiangsu, China discusses the role of LAMP2A protein in mediating autophagy and cisplatin resistance in colorectal cancer. The study found that LAMP2A expression was increased in cisplatin-resistant colorectal cancer and was associated with poor patient prognosis. Inhibition of LAMP2A reduced cancer cell proliferation, migration, invasion, and increased sensitivity to cisplatin. The researchers suggest that targeting LAMP2A activity could be a potential therapeutic strategy for overcoming cisplatin resistance in colorectal cancer. The study was supported by the Guiding project of Jiangsu Provincial Health Commission and has been peer-reviewed. [Extracted from the article]

The University of Birmingham and Orphelia Pharma have extended their collaboration to support the marketing authorization of Kizfizo, a new oral liquid pediatric formulation of temozolomide for the treatment of relapsed or refractory high-risk neuroblastoma. Neuroblastoma is a rare type of cancer that primarily affects children under the age of 2. The collaboration involves leveraging patient-level data from the BEACON refractory or relapsed neuroblastoma trial to assess the clinical benefit and safety of temozolomide-based regimens. The data from the trial will be used to support the registration dossier of Kizfizo. Additionally, Orphelia Pharma has agreed to support the new BEACON-2 trial by making Kizfizo available as a child-friendly temozolomide option. The collaboration between the University of Birmingham and Orphelia Pharma has been instrumental in advancing the development of Kizfizo and improving treatment options for pediatric neuroblastoma patients. [Extracted from the article]

A study from Brown University Warren Alpert Medical School reports on a rare case of an ascending aortic thrombus in a patient with lung cancer. The patient did not have any structural risk factors or receive chemotherapy. The study highlights the need for clinicians to be aware of unusual arterial thromboses in patients with high metastatic burden. Further research is needed to determine the optimal management for an aortic thrombus in the context of malignant disease. [Extracted from the article]

A recent study conducted by researchers at Nanjing Medical University in Jiangsu, China, has found that the protein Nur77 plays a role in the progression of hepatoblastoma (HB), the most common malignant tumor in children under 5 years old. The study showed that Nur77 was downregulated in HB tumors and that manipulating its expression affected the proliferation, migration, and invasion of tumor cells. Additionally, the researchers found that a Nur77 agonist called CsnB enhanced the therapeutic effect of cisplatin, a commonly used chemotherapy drug, on HB tumors. This research provides new insights into the pathogenesis of HB and suggests potential targeted therapies for clinical treatment. [Extracted from the article]

A recent study conducted by researchers at the State University of Campinas (UNICAMP) in Brazil explored the potential of a palladium(II) complex as a treatment for squamous cell carcinoma (SCC) of the tongue. SCC is a common subtype of head and neck cancers, and current treatments include surgery, radiotherapy, and chemotherapy. The researchers found that the palladium(II) complex inhibited the proliferation of SCC cells in vitro, particularly SCC15 cells, but further studies are needed to understand its selectivity and mechanism of action. The study was supported by various organizations, including Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and the International Atomic Energy Agency (IAEA). [Extracted from the article]

Researchers from the Fourth Military Medical University in Shaanxi, China have developed a gold nanoparticle-based radiation-responsive nanovesicle system for lung cancer chemoradiotherapy. The system, called CV-Au NVs, releases the chemotherapeutic drug cisplatin and the poly ADP-ribose polymerase (PARP) inhibitor veliparib in a controlled manner upon irradiation. In vivo studies showed that the system effectively inhibited tumor growth in a lung cancer model. This study provides new insights into designing nanomedicine platforms for chemoradiation therapy, synergizing both chemotherapy and radiation therapy in a spatiotemporally concurrent manner. [Extracted from the article]

A recent study conducted by researchers at Bangladesh University of Engineering and Technology explored the potential of a SiC nanosheet as a drug delivery system for anticancer drugs. Using density functional theory, the researchers investigated the interactions between the nanosheet and the drugs nitrosourea and carmustine. The study found that the adsorption process was energetically favorable and that the nanosheet showed high reactivity towards both drugs. Additionally, the researchers discovered that the nanosheet could be potentially used in phototherapy. This research provides valuable insights into the development of novel nanosheet-based drug delivery systems for cancer treatment. [Extracted from the article]

A recent study conducted at Zhengzhou Central Hospital Affiliated to Zhengzhou University in China explored the role of circ-LDLRAD3 in cisplatin-resistant gastric cancer. The researchers found that circ-LDLRAD3 was overexpressed in cisplatin-resistant gastric cancer tissues and cells. Knocking down circ-LDLRAD3 reduced cisplatin resistance and inhibited cell proliferation, survival, and invasion. The study also identified the miR-588/SOX5 pathway as a key mechanism involved in the development of cisplatin-resistant gastric cancer. These findings suggest that targeting circ-LDLRAD3 may be a potential therapeutic strategy for overcoming cisplatin resistance in gastric cancer. [Extracted from the article]

Researchers at Wenzhou Medical University in China have developed a new nanoparticle delivery system for the cancer drug oxaliplatin. The nanoparticles, made from a modified form of hyaluronic acid, are designed to respond to the tumor environment and release the drug in a targeted manner. In laboratory experiments, the nanoparticles showed greater efficacy in killing cancer cells compared to traditional delivery methods. This study provides a novel strategy for the development of targeted drug delivery systems for cancer therapy. [Extracted from the article]

Researchers at Central South University have reported new findings on nasopharyngeal carcinoma (NPC). The study focused on the sensitivity of NPC cells to cisplatin (DDP) and the role of cancer-associated fibroblasts (CAFs) in modulating ferroptosis, a form of cell death. The researchers found that CAFs secrete high levels of FGF5, which inhibits DDP-induced ferroptosis in NPC cells. This protective effect is mediated through the FGF5/FGFR2 axis and the activation of downstream signaling pathways. The study suggests that targeting the FGF5/FGFR2 axis could enhance DDP sensitivity and reduce side effects in NPC treatment. [Extracted from the article]

A recent study conducted by researchers at the University of Lethbridge in Canada explored the potential synergistic effects of cisplatin, a chemotherapy drug, and high-THC cannabis extract on colorectal cancer cell lines. However, the study found that the combination of the cannabis extract and cisplatin actually worked antagonistically on the tested cell lines. The researchers conducted a comprehensive transcriptomic analysis to understand the underlying molecular mechanisms and found that the interaction between cisplatin and high-THC cannabis extract could be linked to alterations in gene transcription associated with cell death, DNA repair pathways, and drug resistance. This study provides valuable insights into the potential interactions between chemotherapy drugs and cannabis extract in the treatment of colorectal cancer. [Extracted from the article]